SARCODE BIOSCIENCE INC.
LEXINGTON, MA


SARCODE CORPORATION
SARCODE BIOSCIENCE INC. is an Inactive company incorporated on March 4, 2011 with the registered number F11000000963. This Foreign for Profit company is located at 300 Shire Way, Lexington, MA, 02421, US and has been running for fifteen years. There are currently three active principals.

KEY FACTS ABOUT SARCODE BIOSCIENCE INC.

  1. US Businesses
  2. Companies in Florida
  3. Broward County Companies
Company name
SARCODE BIOSCIENCE INC.
Status
Inactive
Filed Number
F11000000963
FEI Number
20-8026085
Date of Incorporation
March 4, 2011
Home State
DE
Company Type
Foreign for Profit

SARCODE BIOSCIENCE INC. NEAR ME

Principal Address
300 Shire Way,
Lexington,
MA,
02421,
US

See Also

SARCO RICA HOLDINGS, LLC SARCOB JAX LLC SARCOH MBX STR, LLC SARCOIDOSIS SUPPORT GROUP OF SOUTH FLORIDA, INC SARCOIDOSIS, TRANSPLANT, ORGAN PROCUREMENT AND CARDIOMYOPATHY FOUNDATION, INC.

Officers and Directors

The SARCODE BIOSCIENCE INC. managed by the three persons from Exton, Lexington on following positions: Secr, Director, President

Jason E Baranski

Position
Secr Active
From
Exton, PA, PA
Jason E Baranski Related Companies
  1. SHIRE-NPS PHARMACEUTICALS, INC.
  2. TAKEDA PHARMACEUTICALS INTERNATIONAL, INC.
  3. SHIRE HUMAN GENETIC THERAPIES, INC.
  4. VIROPHARMA BIOLOGICS, INC.
  5. BAXALTA US INC.
  6. SHIRE HOLDINGS US AG INC.

Jason E Baranski

Position
Director Active
From
Exton, PA, PA
Jason E Baranski Related Companies
  1. SHIRE-NPS PHARMACEUTICALS, INC.
  2. TAKEDA PHARMACEUTICALS INTERNATIONAL, INC.
  3. SHIRE HUMAN GENETIC THERAPIES, INC.
  4. VIROPHARMA BIOLOGICS, INC.
  5. BAXALTA US INC.
  6. SHIRE HOLDINGS US AG INC.

Colleen Tupper

Position
President Active
From
Lexington, MA, MA
Colleen Tupper Related Companies
  1. VIROPHARMA BIOLOGICS, INC.
  2. SHIRE HOLDINGS US AG INC.
  3. SHIRE US INC.



Registered Agent is CT CORPORATION SYSTEM

Address
C/O CT CORPORATION SYSTEM, TALLAHASSEE, FL, 33324

Events

July 20, 2020
WITHDRAWAL
May 21, 2013
NAME CHANGE AMENDMENT

Annual Reports

2020
February 1, 2020
2019
February 6, 2019